Psoriasis treatment with interleukin-23 inhibitors associates with lower likelihood of modifiable cardiovascular risk factors compared to treatment with other biologics: A retrospective cohort study using real-world data Meeting Abstract

publication date

  • September 1, 2025

webpage

published in

start page

  • AB76

end page

  • AB76

volume

  • 93

issue

  • 3